Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-19. (Cancelled)

20. (New) A composition in the form of a free flowing, compressible powder, consisting porous particles and solid lipids that are absorbed in the pores of the particles in melting state.

21. (New) The composition of claim 20 comprising water-insoluble or poorly soluble compounds that dissolve in the melted lipids of claim 1 and are absorbed by a porous powder or a mixture of porous powders.

22. (New) The composition of claim 20 comprising a porous powder or a mixture of porous powders that absorb melted lipids or surfactants.

23. (New) The composition of claim 20 comprising, at least, a compound that dissolves in the melted lipids and forms solutions, micelles, microemulsion or emulsion with the lipids in an aqueous medium.

24. (New) The composition of claim 20 wherein the said composition facilitates formation of solutions, micelles, microemulsions or emulsions of poorly soluble or water-insoluble compounds and the lipids after administration with no need of pre-emulsification of the compounds during formulation.

25. (New) The composition of claim 20 wherein the lipids are amphiphilic compounds.

26. (New) The composition of claim 25, wherein the lipid is Gelucire, vitamin E TPGS, Bay 10, fatty acids, phospholipids, or non-phospholipids.

27. (New) The composition of claim 20, wherein the porous powders are nontoxic solids possessing sufficient specific surface area and pore structure.

28. (New) The composition of claim 27, wherein the specific surface area is larger than 100 m^2/g.

29. (New) The composition of claim 27, wherein the pore structure has a diameter less than 50 nm.

30. (New) The composition of claim 29, wherein the pore structure is alumina, silica or their mixture.

31. (New) The composition of claim 23, wherein the compound is cyclosporine, triamteren, acyclovir, doxorubicin, labetalol, doxepin, methyldopa or pentoxifyll.

32. (New) A pharmaceutical composition comprising the composition of claim 20 and a pharmaceutically acceptable carrier.

33. (New) A method for producing the compositions of claim **21** comprising steps of:

a) Melting the said solid lipid or lipid mixture by heating;

b) Dissolving the said compound in melted lipid or lipid mixtures;

c) Impregnating the said porous powders with the drug-lipid melt; and

d) Cooling the porous powder impregnated with the drug-lipid melt to room temperature to solidify the drug-lipid melt.

34. (New) The method of claim 33, further comprising granulation, capsule filling, tableting, coating and paste making of the produced composition.

35. (New) The composition produced by the method of claim 33.

36. (New) A pharmaceutical composition which comprises the composition of claim 35.

37. (New) The composition of claim 35, formulated in powders, capsules, granules, coated granules, tablets or coated tablets.

38. (New) The formulated composition of claim 37, comprising the excipients selected from the group containing binders, diluents, disintegrants, coating material, and lubricants.